Yourgene

The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.

News items for the in vitro diagnostics industry for the week of August 10, 2020.

Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.

The Clarigene SARS-CoV-2 IVD kit uses two viral RNA targets, nucleocapsid gene N and envelope gene E, which are specific to COVID-19, the firm said.

As reported in April, revenues for the fiscal year ended March 31 totaled £16.6 million ($21.4 million), up from £8.9 million in FY2019.

Yourgene will provide molecular COVID-19 testing to corporate clients of Caxton, who will obtain their results through Hooha Innovations' Prova app.

The test has been developed to run on Illumina's NextSeq 550Dx next-generation sequencing platform and will be prepared for commercial launch in Europe.

News items for the in vitro diagnostics industry for the week of May 25, 2020.

Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2019.

Yourgene will use its manufacturing facility at Citylabs in Manchester to ramp up production of the test, which was developed by Novacyt's Primerdesign division.